Role of Oxidized Lipids in Pulmonary Arterial Hypertension

Salil Sharma; Grégoire Ruffenach; Soban Umar; Negar Motayagheni; Srinivasa T. Reddy; Mansoureh Eghbali

doi:10.1086/687293

journal article Sep 01, 2016

Role of Oxidized Lipids in Pulmonary Arterial Hypertension

Salil Sharma Grégoire Ruffenach Soban Umar Negar Motayagheni

Srinivasa T. Reddy Mansoureh Eghbali

Pulmonary Circulation Vol. 6 No. 3 pp. 261-273 · Wiley

View at Publisher Save 10.1086/687293

Abstract

Pulmonary arterial hypertension (PAH) is a multifactorial disease characterized by interplay of many cellular, molecular, and genetic events that lead to excessive proliferation of pulmonary cells, including smooth muscle and endothelial cells; inflammation; and extracellular matrix remodeling. Abnormal vascular changes and structural remodeling associated with PAH culminate in vasoconstriction and obstruction of pulmonary arteries, contributing to increased pulmonary vascular resistance, pulmonary hypertension, and right ventricular failure. The complex molecular mechanisms involved in the pathobiology of PAH are the limiting factors in the development of potential therapeutic interventions for PAH. Over the years, our group and others have demonstrated the critical implication of lipids in the pathogenesis of PAH. This review specifically focuses on the current understanding of the role of oxidized lipids, lipid metabolism, peroxidation, and oxidative stress in the progression of PAH. This review also discusses the relevance of apolipoprotein A‐I mimetic peptides and microRNA‐193, which are known to regulate the levels of oxidized lipids, as potential therapeutics in PAH.

Topics

No keywords indexed for this article. Browse by subject →

References

161

[1]

10.1172/jci60658

[2]

10.5539/gjhs.v7n4p307

[3]

10.1016/j.ijcard.2006.01.013

[4]

10.1016/j.rdc.2015.01.003

[5]

10.2214/ajr.109.1.107

[6]

10.4103/1817-1737.58953

[7]

10.1111/j.1469-0691.2010.03286.x

[8]

10.1586/ers.11.17

[9]

10.1097/mcp.0000000000000084

[10]

Kovalchin JP "Nitric oxide for the evaluation and treatment of pulmonary hypertension in congenital heart disease" Tex Heart Inst J (1997)

[11]

10.1055/s-2005-916155

[12]

10.1007/s00246-004-0767-5

[13]

10.1183/09031936.00097107

[14]

10.1183/09031936.00124007

[15]

10.1016/j.cellsig.2012.06.007

[16]

10.1161/hypertensionaha.111.171561

[17]

10.1152/ajplung.00114.2005

[18]

10.1016/j.plefa.2011.10.001

[19]

10.3109/10799893.2010.512013

[20]

10.1016/j.prostaglandins.2009.12.007

[21]

10.1002/jcp.21923

[22]

10.1016/j.prostaglandins.2011.11.003

[23]

10.1007/s10495-008-0286-6

[24]

10.1016/j.plefa.2008.11.007

[25]

Li Q "Kv3.4 channel is involved in rat pulmonary vasoconstriction induced by 15‐hydroxyeicosatetraenoic acid [in Chinese with English abstract]" Sheng Li Xue Bao (2006)

[26]

10.1016/j.prostaglandins.2008.09.005

[27]

10.1093/jb/mvq010

[28]

10.1002/jcp.24443

[29]

10.1086/683695

[30]

10.1126/scitranslmed.3006674

[31]

10.1111/j.1748-1716.1980.tb06696.x

[32]

10.1016/0090-6980(80)90055-6

[33]

10.1194/jlr.m024398

[34]

10.1161/01.res.0000073585.50092.14

[35]

10.1152/ajplung.00199.2009

[36]

An antiproliferative BMP-2/PPARγ/apoE axis in human and murine SMCs and its role in pulmonary hypertension

Georg Hansmann, Vinicio A. de Jesus Perez, Tero-Pekka Alastalo et al.

Journal of Clinical Investigation 10.1172/jci32503

[37]

10.1155/2013/903947

[38]

10.1165/rcmb.2008-0132oc

[39]

10.1164/rccm.201108-1536pp

[40]

10.1378/chest.09-2815

[41]

10.1007/s00109-009-0524-6

[42]

10.1007/s00109-010-0679-1

[43]

10.1164/rccm.201306-1086oc

[44]

10.1164/rccm.201312-2240ed

[45]

10.1126/scitranslmed.3001327

[46]

10.2340/00015555-1680

[47]

10.1152/ajplung.00142.2006

[48]

10.1038/sj.bjp.0703784

[49]

10.1016/j.freeradbiomed.2006.05.035

[50]

10.1074/jbc.m111634200

Showing 50 of 161 references

Metrics

43

Citations

161

References

Details

Published: Sep 01, 2016
Vol/Issue: 6(3)
Pages: 261-273
License: View

Authors

S

Salil Sharma